Tricuspid regurgitation management includes surgery during left-sided valve procedures, while new percutaneous approaches are emerging for primary cases despite a lack of long-term data.
This review highlights the clinical importance of tricuspid regurgitation, current surgical guidelines, and the need for long-term data on emerging percutaneous therapies.
The tricuspid valve was virtually ignored for a long time in the past. However, significant tricuspid regurgitation (TR) often accompanies left-side heart valve pathology and does not always reverse with its correction. If left untreated, TR can progress and result in progressive right ventricular failure. Current guideline recommendations still hold minor differences. Nevertheless, there is a consensus to operate on patients with severe TR undergoing left-sided valve surgery (class I) or those with mild to moderate TR with a dilated annulus (≥40 or ≥21 mm 2 , Class IIa). However, in case of the primary TR, surgical options is limited by a relatively high risk of mortality and morbidity. For these patients, new percutaneous approaches are becoming available but no long-term data are still available. In this review, we provide a comprehensive overview of the epidemiological and pathophysiological aspects of TR, and the current and future directions of therapy.
Mangieri et al. (Sat,) conducted a review in Tricuspid regurgitation. Tricuspid valve surgery and percutaneous approaches was evaluated. Tricuspid regurgitation management includes surgery during left-sided valve procedures, while new percutaneous approaches are emerging for primary cases despite a lack of long-term data.